Naloxone hydrochloride

TUESDAY, Feb. 24, 2026 — Hurricanes are terrifying and destructive, but their damage doesn’t end with homes flattened and cities flooded, a new study says. A wave of alcohol- and drug-related deaths also occur in the wake of hurricanes and tropical storms, researchers reported Feb. 20 in JAMA Network Open . Further, these deaths increase as people are exposed to more and longer storms. “Among U.S. counties exposed to tropical cyclones from 1988 to 2019, each additional cyclone-exposed day per month was associated with an increase in psychoactive drug-related death rates,” concluded a team led by Raenita Spriggs , a doctoral student at Columbia University Mailman School of Public Health in New York City. “The associations were greatest in the month of exposure and, in some cases, persisted for up to three months post cyclone,” the researchers found. These results are disturbing, given that such storms are growing in number and intensity due to climate change, said Dr. Manassa Hany , director of addiction psychiatry at Zucker Hillside and South Oaks hospitals at Northwell Health in New York City, who reviewed the findings. “We've always anecdotally suspected that this is the case — if there is a large-scale disaster happening somewhere; that it will lead to problems with substance use disorder and mental health in general,” Hany said. He was not involved in the research. For the new study, researchers analyzed nearly 800,000 substance-related deaths in more than 1,250 U.S. counties that experienced a tropical storm from 1988 to 2019. Results showed that for every day a storm wreaked havoc on a county, the substance-related death rate increased by 3.8% both that month and the month after. Interestingly, only wealthier counties were affected by this increase in substance-related deaths, researchers found. “Lower poverty, predominantly white communities have greater access to prescription drugs, higher rates of prescription drug misuse concurrent with illicit drug use, and higher rates of substance use disorders, which may increase the risk of misuse or overdose when health care systems are disrupted and prescriptions become unmonitored,” researchers wrote. “Additionally, individuals with higher socioeconomic status are more likely to use tranquilizers (e.g., Xanax ), stimulants (e.g., cocaine), and alcohol,” the team continued. “The ability to purchase and access these substances may be greater in wealthier communities, and disruptions in local drug markets during and after cyclones may increase reliance on more dangerous or adulterated substances.” There are a couple of potential explanations why tropical storms might cause an increase in deadly alcohol and drug use, Hany said. These storms cause considerable anxiety and stress, leading some to self-medicate with drinking and drugs, he said. “People may crave something to enter their system and calm them down and numb their feelings,” Hany said. “For those who have substance use disorders and recovery or preexistent substance use disorders, it will promote relapse.” Hurricanes also can disrupt addiction services like treatment centers, Hany said. “If [someone is] getting methadone from an opioid treatment program, it would shut down. If someone is getting suboxone from their doctor, they probably will lose access to that treatment,” he said. “During the time of a natural disaster, people will not be receiving formal treatments such as counseling and group sessions. Their usual treatment process and support will be interrupted.” Hany said that interruption can promote drug cravings that could lead to overdoses. “People may also lose access to naloxone to revive people if an overdose happens because of a severe weather event,” he said. These results show that substance use and mental health services need to be integrated into disaster response plans, researchers said. Hany agreed. “When we prepare for a disaster, we must make sure that people are safe and have a place to shelter, but also make sure that we plan for higher rates of overdose,” Hany said. “When an area is going to be hit with severe weather, we need to make sure the shelters have harm reduction resources such as Narcan, first responders, community aid organizations. We need to equip them.” Sources JAMA Network Open, Feb. 20, 2026 Dr. Manassa Hany, director of addiction psychiatry, Zucker Hillside and South Oaks hospitals, Northwell Health, New York City

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation. The FDA determined that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is bioequivalent and therapeutically equivalent to Boehringer Ingelheim's Atrovent ® HFA Inhalation Aerosol. Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with Paragraph IV certification. This exclusivity period will begin on the first day that Amphastar's Ipratropium Bromide HFA Inhalation Aerosol is commercially launched. "We are excited to announce FDA approval of Ipratropium Bromide HFA Inhalation Aerosol, reinforcing the strength of our integrated R&D and manufacturing model and demonstrating our ability to deliver complex, high-value generics," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "We expect this launch to contribute meaningfully to our respiratory portfolio and to further strengthen our long-term growth strategy, capabilities and commitment to delivering impactful therapies to patients as we increase our efforts on the development of proprietary pipeline candidates." Ipratropium is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. According to IQVIA, the U.S. sales for Atrovent ® HFA were approximately $112 million for the 12 months ended December 31, 2025. Amphastar plans to launch its Ipratropium Bromide HFA Inhalation Aerosol, previously referred to as AMP-007, early in the second quarter of 2026. Pipeline Information The Company currently has one ANDA and one biosimilar insulin filed with the FDA targeting products with a combined market size of over $1.7 billion, along with two biosimilar products in development targeting products with a market size exceeding $3.7 billion, and two generic products in development targeting products with a market size of over $1 billion. This market information is based on IQVIA data for the 12 months ended December 31, 2025. The Company is developing multiple proprietary products with injectable and intranasal dosage forms. The Company's proprietary pipeline also includes four recently in-licensed products including three proprietary peptides targeting oncology and ophthalmology indications, and a fully synthetic corticotropin compound designed to address inflammatory and autoimmune conditions. About Amphastar Pharmaceuticals, Inc. Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at . Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ® , BAQSIMI ® , Primatene MIST ® , REXTOVY ® , Amphadase ® , Ampsilog TM and Cortrosyn ® , are the property of Amphastar. Forward-Looking Statements All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high-quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 7, 2025, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and our other filings or reports that we may the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI ® . You can locate these reports through our website at and on the SEC's website at . The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change. Contact Information: Amphastar Pharmaceuticals, Inc. Bill Peters Chief Financial Officer (909) 476-3416 SOURCE: Amphastar Pharmaceuticals, Inc. View the original press release on ACCESS Newswire